Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
146. |
ECCT/19/11/04 | Second line switch to Dolutegravir (2SD) study Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial |
Principal Investigator(s) 1. Loice Achieng Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Thika Level 5 Hospital (Kiambu county) 4. Kiambu Level 5 Hospital (Kiambu county) |
View |
147. |
ECCT/22/02/02 | The Women TAF-FTC Benchmark Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
View |
148. |
ECCT/15/01/02 | Study title An observational pilot study to characterize the immune response induced by the commercial Varicella Zoster Virus vaccine Zostavax® (Merck) in healthy adult females in Nairobi, Kenya. Clinical Phase IV |
Principal Investigator(s) 1. Prof Walter Jaoko Jaoko Site(s) in Kenya KAVI-INSTITUTE OF CLINICAL RESEARCH (KAVI-ICR) |
View |
149. |
ECCT/22/03/08 | CVIA 092 “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”. |
Principal Investigator(s) 1. Dr Lucy Koech Chepkurui Koech Site(s) in Kenya KEMRI/ KERICHO CRC |
View |
150. |
ECCT/25/02/03 | NOZE20240219TB “Validation of a Digital Olfaction Based Breathalyzer Device for Non-Invasive Detection of Volatile Biomarkers in Patients with and without Tuberculosis: Case Control Study”. |
Principal Investigator(s) 1. Ibrahim Daud Site(s) in Kenya KEMRI/WRP CRC Kericho |
View |